#Singapore #diabetes management #ALR Technologies #CGM Medical Technology

ALR Technologies Announces Acquisition of CGM Medical Technology

In a landmark move to bolster its position in the diabetes management sector, ALR Technologies SG Ltd (commonly known as ALRT) has entered into a Letter of Intent (LOI) to acquire CGM Medical Technology Singapore Pte. Ltd. and its Shenzhen counterpart for a total package of $45 million and 200 million ordinary shares. This acquisition is poised to make ALRT a fully integrated company in the diabetes management arena, allowing for enhanced control over its products and services.

Strategic Intent Behind the Acquisition

Sidney Chan, Chairman and CEO of ALRT, expressed optimism about this acquisition stating, "The integration of CGM Medical will enable us to manage our continuous glucose monitoring technology from the ground up." By acquiring CGM Medical's intellectual property, ALRT will enhance its product offerings, specifically the GluCurve Pet CGM, and is set to launch future systems targeting human health. This advancement is expected to streamline production while improving profit margins.

Financial Details and Future Projections

The LOI stipulates that ALRT will issue 200 million ordinary shares as payment upon finalizing a definitive agreement. Moreover, it plans to make an additional $40 million payment via an unsecured, non-interest-bearing promissory note, reflecting the commitment towards solidifying its acquisition strategy. Furthermore, the deal includes assets from CGM Medical Shenzhen, expandable upon reaching 500,000 CGMs production capacity per month.

Upon completion, ALRT will generate cash flow amounting to 25% of its earnings until fulfilling its entire payment obligations associated with the acquisition. This structured payment approach demonstrates the company’s strategy of reinvesting profits towards growth and ensuring financial robustness throughout the integration process.

Construction of State-of-the-Art Facility

One of the critical moves post-acquisition is ALRT's plan to establish a world-class manufacturing facility in the Johor-Singapore Special Economic Zone (JS-SEZ). This facility will harness the expertise of CGM Medical, utilizing advanced technology and skilled personnel in the production of glucose monitoring devices. ALRT anticipates reaching a monthly production target that would cater to both veterinary and human healthcare markets.

Additionally, ALRT has started procuring equipment valued at $1.65 million for the Shenzhen operations. The elevation of production capacity to 300,000 units per month is crucial for supporting its commitment to the GluCurve CGM projects.

Due Diligence and Regulatory Approvals

The successful closing of this acquisition hinges on various conditions, including comprehensive due diligence, regulatory approvals, and execution of the final agreements. ALRT is on track to finalize negotiations and anticipates securing all necessary approvals by July 31, 2026. The expected completion date following that is set for August 31, 2026.

In addition to operations in Singapore, the acquisition scope includes extensive collaboration with CGM Medical Shenzhen, indicating a robust strategy for international presence in diabetes management solutions.

Future Implications for Diabetes Management

By integrating CGM Medical Technology into its framework, ALRT strengthens its ability to provide innovative and tailored solutions for diabetes care. With this acquisition, ALRT aligns itself to harness advanced technologies that could soon redefine diabetes monitoring paradigms, both for pets and humans.

As this deal progresses, stakeholders are looking forward to the enhanced capabilities and potential breakthroughs in diabetes management and care.